Rexahn Pharmaceuticals Announces Leadership Transition

Nov 14, 2018

Rexahn Reports Third Quarter 2018 Financial Results

Nov 5, 2018

Rexahn Announces $7.5 Million Registered Direct Offering

Oct 17, 2018

Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data from Ongoing Phase 2a Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer

Oct 2, 2018

Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium

Sep 18, 2018

Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Aug 30, 2018

Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer

Aug 21, 2018

Rexahn Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans

Aug 7, 2018

Rexahn Reports Second Quarter 2018 Financial Results

Aug 6, 2018

Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018

Jun 14, 2018